Sionna Therapeutics, Inc. Common Stock

Sionna Therapeutics will cut about 46% of its workforce after its cystic fibrosis pipeline suffered a key clinical setback, sending SION shares down nearly 17% yesterday. The restructuring, which Sionna expects to cost approximately $6.4 million, is aimed at lowering operating expenses and focusing resources on its prioritized CF programs, and the company says the measures should extend its cash runway into the second half of 2029. The move follows disappointing results for SION-719, a nucleotide binding domain 1 stabilizer tested as an add-on to Vertex Pharmaceuticals' marketed CF treatment Trikafta in adults homozygous for the F508del mutation; the phase IIa PreciSION CF proof-of-concept study missed its key endpoint, failing to show a statistically significant reduction in sweat chloride levels, and Sionna decided not to continue developing the candidate as a Trikafta add-on. A post-hoc analysis that excluded three participants showed a placebo-adjusted sweat chloride reduction of 8.6 mmol/L, but the company noted this was not the prespecified primary analysis and is therefore less conclusive. Sionna is now concentrating on its proprietary dual combination of SION-451 and SION-2222, which it selected as its preferred combination after a phase I study met safety, tolerability and pharmacokinetic objectives, and it intends to advance the pair into the phase IIa AscenSION CF proof-of-concept study in the first quarter of 2027. Year to date, SION's stock has plunged 83.3% against the industry's 7.8% growth.

Sionna Therapeutics shares plunged more than 90% after its lead cystic fibrosis drug candidate SION-719 failed a Phase 2a trial, while Vertex Pharmaceuticals surged to new highs as a key competitive threat was removed. The trial, which tested SION-719 as an add-on to Vertex’s blockbuster Trikafta regimen, did not meet its main activity endpoint, and Sionna will not advance the program. Sionna will now prioritize an earlier-stage SION-451 combo program, but with over $268 million in cash and its lead asset shelved, the stock’s valuation was heavily dependent on SION-719. Vertex, already trading near record levels after raising full-year revenue guidance and proposing a $10 billion acquisition of Crinetics Pharmaceuticals, saw its cystic fibrosis dominance further de-risked.

Several stocks made significant midday moves on Monday. MarineMax soared 46% after agreeing to be sold to Blackstone Infrastructure's Safe Harbor Marinas for $53 a share in cash, or $1.5 billion, with the deal expected to close by the end of 2026. Varex Imaging climbed 48% after Teledyne Technologies agreed to buy the imaging component maker for $18.90 a share in cash, a deal expected to close in early 2027. Sionna Therapeutics collapsed 92% after its cystic fibrosis drug failed to meet key endpoints in a proof-of-concept trial, and the company said it would not advance the drug. Other notable movers included NetApp, which gained 6% after Morgan Stanley upgraded it to equal weight from underweight, and Verisk Analytics, which tumbled more than 5% after a Delaware judge ruled it must proceed with a $2.35 billion acquisition of AccuLynx. Apple dipped 2% after Jefferies downgraded the stock to underperform from hold, citing canceled plans for an all-glass iPhone. Intel fell nearly 3% after announcing a $15 billion common stock offering for general corporate purposes.

Vertex Pharmaceuticals shares surged approximately 5.9% in Monday's regular session after Sionna Therapeutics announced its drug SION-719 missed the key activity endpoint in a Phase 2a trial when added to the current standard of care. Sionna is dropping that specific add-on strategy, giving Vertex's dominant cystic-fibrosis franchise more breathing room. Vertex's second-quarter revenue climbed 12% to roughly $3.33 billion, and management raised full-year revenue guidance to $13.1 billion to $13.2 billion. Despite the stock's jump, GuruFocus estimates Vertex's GF Value at $519.20, leaving the shares trading only 1.34% above that fair value estimate at $526.15.

Tenax Therapeutics and Sionna Therapeutics shares plunged in premarket trading after their respective clinical trials failed, while MarineMax jumped on a reported buyout by Blackstone-owned Safe Harbor Marinas. Tenax stock fell 84.2% after its Phase 3 LEVEL trial of TNX-103 missed its primary endpoint, showing no statistically significant improvement in six-minute walk distance versus placebo with a p-value of 0.63. Sionna shares dropped 92.1% after its Phase 2a trial of SION-719 failed to demonstrate meaningful CFTR function improvement, with a placebo-adjusted sweat chloride change of just -1.0 mmol/L and a p-value of 0.7. MarineMax surged more than 34% after Reuters reported Safe Harbor is close to acquiring the boat retailer for $1.5 billion including debt, or about $53 per share in cash, a substantial premium to Friday's close of $35.68. AAON gained over 10.6% after its second-quarter results apparently beat expectations, while Silence Therapeutics rose 16.2% ahead of a conference call on its Phase 2 SANRECO trial. Dole fell 4.2% after missing second-quarter earnings and revenue estimates, and AirSculpt Technologies dropped 18.4% on weaker quarterly results with revenue down 3% year-over-year.